Assessing the impact of compliance packaging on hemoglobin A1c in diabetic patients receiving oral antiglycemic medications. Kandon P. Render, PharmD; Joshua Kinsey, PharmD; Sharon Sherrer, PharmD Mercer University School of Pharmacy - Atlanta, GA
Background/Purpose: An IRB-approved studying evaluating the effect of the use of compliance packaging on hemoglobin A1c in patient's with type 2 diabetes mellitus.
Methodology: The design of the study is a randomized controlled pilot study comprised of diabetic patients receiving oral antiglycemic medications. The study consists of a study group and a control group: patients initiated on compliance packaging and patients receiving no compliance packaging. Patients were excluded if they had any medication changes within three months prior to enrollment. Upon consent and enrollment in the study, a baseline A1c, or an A1c collected within the past three months, was obtained from the patient or their provider. Patients in the compliance packaging group were then initiated on compliance packaging. Patients in the control group continued taking their medications per usual. After 3 months, another A1c was obtained from the patient or their providers. A1c values will also be obtained at 6 months and 9 months, if collected by the patient_x0019_s providers.
Results: Sixteen patients were included in this study. The mean baseline A1c in the control and study groups were 7.35 and 7.56, respectively. The mean number of antiglycemic medications in the control and study groups were 2.4 and 2.67 medications, respectively.
Presentation Objective: Describe the impact that the use of compliance packaging has on hemoglobin A1c in patients with type 2 diabetes.
Self-Assessment: What ways can a community pharmacist positively influence the outcomes of patients with type 2 diabetes?
